Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults

Clinical Orthopaedics and Related Research

Volumn 466, Issue 6, 2008, Pages 1292-1301

  Hugate, Ronald R ^a   Wilkins, Ross M ^a   Kelly, Cynthia M ^a   Madsen, Walt ^a   Hinshaw, Ioana ^a   Camozzi, Anne B ^a  

^a PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTERIOGRAPHY; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OTOTOXICITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ARTICLE; BONE TUMOR; BONES OF THE ARM AND HAND; CLINICAL TRIAL; COHORT ANALYSIS; DRUG ADMINISTRATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEG; MIDDLE AGED; RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARM BONES; BONE NEOPLASMS; CISPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LEG BONES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OSTEOSARCOMA;

EID: 44949085562     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-008-0252-1     Document Type: Conference Paper

References (52)

1. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
2. Bacci G, Ferrari S, Forni C, Mercuri M, Picci P, Bertoni F, Capanna R, Manfrini M, Donati D, Brach Del Prever A, Baldini N. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute. Chir Organi Mov. 1996;81:369-382.
3. Bacci G, Ferrari S, Longhi A, Forni C, Bertoni F, Fabbri N, Zavatta M, Versari M. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93-99.
4. Bacci G, Ferrari S, Mercuri M, Longhi A, Capanna R, Tienghi A, Brach del Prever A, Comandone A, Cesari M, Bernini G, Picci P. Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study. Acta Oncol. 1998;37:41-48.
5. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities. A 27-year experience in a single institution. J Surg Oncol. 2007;96:118-123.
6. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Fifteen year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161.
7. Benjamin RS, Chawla SP, Carrasco CH, Raymond AK, Murray JA, Armen T, Patel S, Wallace S, Ayala A, Papadopoulos NE, et al. Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cisplatinum. Ann Oncol. 1992;3(Suppl 2):S3-S6.
8. Bentzen SM, Poulsen HS, Kaae S, Jensen OM, Johansen H, Mouridsen HT, Daugaard S, Arnoldi C. Prognostic factors in osteosarcomas: a progression analysis. Cancer. 1988;62:194-202.
9. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
10. Brosjö O. Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group experience. Acta Orthop Scand. 1999;285(Suppl):58-61.
11. Carrasco CH, Charnsangavej C, Raymond AK, Richli WR, Wallace S, Chawla SP, Ayala AG, Murray JA, Benjamin RS. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology. 1989;170:839-842.
12. Cores EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA. 1972;221:1132-1138.
13. Cullen JW, Jamroz BA, Stevens SL, Madsen W, Hinshaw I, Wilkins RM, Cullen P, Camozzi AB, Fink K, Peck SD, Kelly CM. The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration and prediction of necrosis. J Vasc Interv Radiol. 2005;16:1107-1119.
14. Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101-110.
15. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
16. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard D. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241-246.
17. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-120.
18. Ettinger LJ, Douglass HO, Higby DJ. Adjuvant Adriamycin and Cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer. 1981;47:248-254.
19. Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D, Gasbarrini A, Tienghi A, Brach del Prever A. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765-771.
20. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity. An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145-1150.
21. Ferrari S, Mercuri M, Picci P, Bertoni F, Brach del Prever A, Tienghi A, Mancini A, Longhi A, Rimondini S, Donati D, Manfrini M, Ruggieri P, Biagini R, Bacci G. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intra-arterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.
22. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, Cisplatin, and doxorubicin for patients with localized ostesarcoma of the extremity. A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.
23. Franzius C, Scluk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
24. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
25. Honegger HP, Cserhati MD, Exner GU, von Hochstetter A, Groscurth P. Zürich experience with preoperative, high dose methotrexate-containing chemotherapy in patients with extremity osteosarcomas (OSA). Ann Oncol. 1991;2:489-494.
26. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 10 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
27. Jaffe N, Knapp J, Chuang VP, Wallace S, Ayala A, Murray J, Cangir A, Wang A, Benjamin RS. Osteosarcoma. Intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum II (CDP); angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51:402-407.
28. Jaffe N, Raymond AK, Ayala A, Carrasco CH, Wallace S, Robertson R, Griffiths M, Wang YM. Effect of cumulative courses of intra-arterial cis-diamminedichloroplatinum II on the primary tumor in osteosarcoma. Cancer. 1989;63:63-67.
29. Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, Anzai T, Cangir A, Wang YM, Chen T. Comparison of cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol. 1985;3:1101-1104.
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997;337:216-225.
32. Knop J, Delling G, Heise U, Wingler K. Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99 mTc-methylene diphosphonate parametric imaging with surgical histopathology. Skeletal Radiol. 1990;19:165-172.
33. Kunisada T, Ozaki T, Kawai A. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: angiography compared with thallium-201 scintigraphy. Cancer. 1999;86:949-956.
34. Lang P, Grampp S, Vahlensieck M. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol. 1995;165:135-142.
35. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy. A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-128.
36. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286-291.
37. Mavligit GM, Benjamin RS, Patt YZ. Intra-arterial cis-platinum for patients with inoperable skeletal tumors. Cancer. 1981;48:1-4.
38. Mercuri M, Capanna R, Manfrini M, Bacci G, Picci P, Ruggieri P, Ferruzzi A, Ferraro A, Donati D, Biagini R, de Maio M, Cazzola A, Campanacci M. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res. 1991;264:156-168.
39. Mirra JJ, Picci P, Gold RH. Bone Tumors: Clinical, Radiologic, and Pathologic Correlations. Vol 1. Philadelphia, PA: Lea & Febiger; 1989:255-344, 766-794.
40. Nair N, Ali G, Green AA. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin Positron Imaging. 2000;3:79-83.
41. Nitschke R, Starling KA, Vats T, Bryan H. Cis-diamminedichloroplatinum (NSC 119875) in childhood malignancies: A Southwest Oncology Group Study. Med Pediatr Oncol. 1978;4:127-132.
42. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy. A report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
43. Quintana J, Beresi V, DelPozo H, Latorre JJ, Henriquez A, Chamas N, Diaz V, Geldres V, Sepulveda L, Macho L, Dolz G. Intra-arterial cisplatin given prior to surgery in osteosarcoma: grade of necrosis and size of tumor as major prognostic factors. Am J Pediatr Hematol Oncol. 1991;13:269-273.
44. Rha SY, Chung HC, Gong SJ, Shim KY, Ahn JB, Yang WI, Shin KH, Yoo NC, Kim JH, Roh JK, Lee CI, Kim BS. Combined preoperative chemotherapy with intra-arterial Cisplatin and continuous intravenous Adriamycin for high grade osteosarcoma. Oncol Rep. 1999;6:631-637.
45. Rosen G, Caparros B, Nirenberg A. The successful management of metastatic osteogenic sarcoma: A model for the treatment of primary osteogenic sarcoma. In: van Oosterom AT, Muggia FM, Cleton FJ, eds. Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas. Boston, MA: Leiden University Press; 1979:349-366.
46. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma - the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2192.
47. Schulte M, Brecht-Krauss D, Werner M. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET. J Nucl Med. 1999;40:1637-1643.
48. Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, Calvo D 3rd, Samuels M, Bonura J, Loo TL. Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum (II). Cancer Res. 1983;43:917-920.
49. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997;79:411-415.
50. Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res. 2005;438:128-136.
51. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens SL, Kelly CM, Camozzi AB. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10:498-507.
52. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, Jürgens H, Ritter J, Kusnierz-Glaz C, Erttmann R, Gadicke G, Graf N, Ladenstein R, Leyvraz S, Mertens R, Weinel P. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer. 1990;66:1703-1710.